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Central sensitivity syndromes (CSS) include ﬁbromyalgia syndrome (FMS), irritable bowel syndrome, temporomandibular
disorder, restless legs syndrome, chronic fatigue syndrome, and other similar chronic painful conditions that are based on central
sensitization(CS).CSSaremutuallyassociated.Inthispaper,prevalenceofFMSamongothermembersofCSShasbeendescribed.
An important recent recognition is an increased prevalence of FMS in other chronic pain conditions with structural pathology, for
example, rheumatoid arthritis, systemic lupus, ankylosing spondylitis, osteoarthritis, diabetes mellitus, and inﬂammatory bowel
disease. Diagnosis and proper management of FMS among these diseases are of crucial importance so that unwarranted use of
such medications as corticosteroids can be avoided, since FMS often occurs when RA or SLE is relatively mild.
1. Introduction:HistoricalOverviewand the
Importance of Nomenclatures
Thefactthatﬁbromyalgiasyndrome(FMS)isassociatedwith
several similar conditions without structural pathology was
ﬁrst reported in a controlled study in 1981 [1], following
which a conceptual model was proposed with a Venn dia-
gram, showing the mutual overlaps in these syndromes [2].
Since then, a large number of studies have conﬁrmed these
associations, compared with both healthy controls as well as
diseases with structural (the so-called “organic”) pathology
(DWSP) [3, 4]. (Although there are structural changes,
e.g., decreased hippocampus and gray matter volume in
some CSS conditions, these changes seem to result from
prolonged central sensitization (CS) and will be discussed
at the end.) These overlapping conditions are collectively
knownascentralsensitivitysyndromes(CSS)[5–8],sinceCS
is the common binding glue between them. The term CSS
was ﬁrst coined in 2000 [5] and has been reviewed [5–8]. We
[6]andothers[9]havedescribedmutualassociationsamong
the CSS conditions.
In contrast to association of FMS with other CSS mem-
bers, association of FMS with DWSP was reported somewhat
later[10]andmorefrequentlyonlyinrecentyears.Wolfeand
CatheyweretheﬁrsttorecognizetheassociationofFMSwith
rheumatoid arthritis (RA) [10]. Although they were called
“secondary ﬁbrositis,” these were cases of concomitant FMS
with typical symptoms and multiple tender points (TP) in
association with RA. The diagnosis of FMS in the pre-1990
ACR criteria era was made on the characteristic symptoms of
F M Sa sw e l la sm a n yt e n d e rp o i n t s[ 10].
What’s in a name? Asked Shakespeare rhetorically in
Romeo and Juliet. My own answer is “A lot.” A name should
be meaningful, tell the gist of the topic, and must not distort
the underlying truth, recognizing that scientiﬁc truth is not
carved in rock and does change over time. In this discourse, I
shall use the terms syndrome, illness, condition, and disease
synonymously. Further, since the term ﬁbromyalgia implies
nothing more than pain as has been discussed by Fitzcharles
and Yunus in this issue of the journal, I prefer the term
“ﬁbromyalgia syndrome” since FMS is so much more than
pain with a large number of other distressing symptoms.
Elsewhere, I have argued that diﬀerentiation between
illness and disease is artiﬁcial and contrary to patient
interestandhamperspropermanagementofCSSconditions,
since anything that is not currently viewed as a disease
(i.e., does not have structural pathology, e.g., inﬂammation,
degeneration, or neoplasm) is viewed as predominantly2 Pain Research and Treatment
or exclusively psychological and benign and is not taken
seriously by the health care providers, accentuating the
suﬀering of the patients [7]. In an irresponsible way, this
untruthful“dogma”ispasseddownfromtheprofessororthe
attending to the students, and the victims are our patients.
I have also rationalized that the use of the term “organic”
for DWSP is irrational, since organs are involved in both CSS
and DWSP—functional changes in the former and structural
in the latter [7]. In the same context, the use of the nosology
“functional” for CSS is antithetical, since the neurochemical-
endocrine status of organs involved in CSS is dysfunctional!
Such nomenclatures as “medically unexplained symp-
toms” or MUS and “somatization disorder” (SD) are equally
fallacious and detrimental to scientiﬁc progress, and state-
ments of bias. Such a bias impedes empathetic and proper
patient care. By DSM IV-TR deﬁnition, in SD “laboratory
tests are remarkable for the absence of ﬁndings to support
subjective symptoms.” This is obviously not true of CSS dis-
eases as has been adequately discussed [7]. CSS are medical
conditions based on objective pathology of neurochemistry
and neuroimaging that explain many symptoms of CSS
diseases [7]. So, terms like MUS seem to sprout in a fertile
mind of bias. The problem is that MUS represents illness and
illness is a second class citizen in the land of medicine.
2.MaterialsandMethods: Processof
LocatingArticlesforThisReviewand
t h eA u t h o r’ sOwnV ie ws
Several sources of literature search were employed: PubMed,
ScienceCitationIndex—ISIWebofKnowledgeandCINAHL
Plus. A large number of key words were used, includ-
ing ﬁbromyalgia, ﬁbromyalgia syndrome, functional syn-
dromes, somatic syndromes, medically unexplained symp-
toms, CS, central sensitivity syndromes, overlapping con-
ditions, chronic pain, individual members of central sensi-
tivity syndromes (e.g., irritable bowel syndrome, headaches,
migraine, temporomandibular disorder, myofascial pain
syndrome,restlesslegssyndrome,vulvodynia,andinterstitial
cystitis), chronic back pain, chronic neck pain, chronic
pelvic pain, and chronic disease, as well as a number of
chronic pain conditions with structural pathology (e.g.,
RA, systemic lupus erythematosus, osteoarthritis, ankylosing
spondylitis, diabetes mellitus, ulcerative colitis, Crohn’s dis-
ease, endometriosis, carpel tunnel syndrome, and neuritis).
Additionally,allreferencesofagivenarticleweresearchedfor
an additional source. Finally, this paper adds my own ideas.
3.FMS inCSSDiseases:Associations
AreBidirectional
CSS conditions include FMS, irritable bowel syndrome
(IBS),functionaldyspepsia,chronicfatiguesyndrome(CFS),
myogenic temporomandibular disorder (TMD), tension-
type headache, migraine, regional pain syndromes (myofas-
cial pain syndrome and neck and back pain without
structural pathology), restless legs syndrome, interstitial
cystitis, multiple chemical sensitivity, posttraumatic stress
disorder (PTSD), Gulf War syndrome, and vulvodynia [6–
9]. Undoubtedly, the number will grow by the Yunus criteria
for CSS [6]. Although the literature is ripe with reports
of increased prevalence of various members of CSS in
FMS (too many to provide references), reports on their
bidirectionalinterrelationshipsarerelativelyfew[6,9].Thus,
while prevalence of irritable bowel syndrome (IBS) in FMS is
increased compared with controls [1, 3–9], same is also true
forFMSinapopulationofIBSandotherCSSmembers,such
as (TMD) (see below).
StudiesoftheoccurrenceofFMSinotherCSSconditions
are generally limited at this time (compared with prevalence
of CSS in FMS). Number of studies is indicated by the
number of references (Table 1). Increased prevalence of
FMS, either by the use of a healthy control group or
by consideration of the prevalence of FMS in the general
population, has been reported in IBS [9, 11–14], TMD
[9, 15–19], headaches [9, 20–23] (including tension-type
headache, migraine, and a mixed group of TTH and
migraine), interstitial cystitis [9, 24–27], chronic fatigue
syndrome [9, 28, 29], vulvodynia/vulvar vestiular syndrome
[30, 31] ,a n dG u l fW a rs y n d r o m e[ 32–34].
Sixty-seven percent of patients who present with “idio-
pathic” chronic low back pain were found to have FMS
[9]. Patients presenting with chronic low back or neck pain
demonstrateevidenceofCS[6,8,9],andthesepatientsoften
develop widespread pain and ﬁbromyalgia at a later time
[6, 35].
MPS and FMS are overlapping syndromes [6]. There is
strong evidence for CS in MPS, including decreased pain
threshold by various nociceptive stimuli at sites remote from
painfularea,accentuatedspinalnociceptiveﬂexionreﬂex[6],
and augmented cortical activation by functional magnetic
resonance imaging (fMRI) [6, 36].
Most cases of FMS begin with regional pain similar to
MPS. Trigger points (TrP), in addition to tender points (TP),
are also present in FMS [37]. It has been suggested that a
continuous input from a TrP leads to, and maintain, CS both
in MPS and FMS [37]. The cause of TrP is speculative but
include local trauma (including fall, motor vehicle accident,
overuse, and repetitive use), spinal stress (e.g., scoliosis or
poor posture), and perhaps systemic factors, for example,
mental stress. TrP are likely sustained by CS [36].
4. FMS inChronicPainfulDiseaseswith
StructuralPathology: AnExpansionof
the Fibromyalgia Territory
As early as 1983, Wolfe and Cathey recognized the concomi-
tant occurrence of FMS among RA patients. It was an astute
observation since many features of FMS, for example, pain at
multiple sites (including bursal and tendon areas), fatigue, a
feeling of malaise and tenderness at multiple spots, including
joint areas, may also be present in RA itself. What was not
deﬁnitely known at that time is whether RA patients were
alsotenderinmusclesandothersitesoftypicaltenderpoints.
As it turned out, multiple TPs are a unique feature of FMS,Pain Research and Treatment 3
Table 1: Prevalence of ﬁbromyalgia syndrome (FMS) in other central sensitivity syndromes (CSS) conditions.
CSS condition∗ % prevalence of FMS (mean) % prevalence of FMS (range) Reference no.
Irritable bowel syndrome 40.7 20.0–65.0 [9, 11–14]
Temporomandibular disorder 23.7 13.0–52.0 [9, 15–19]
Headaches (all) 26.3 10.0–40.0 [9, 20–23]
Tension-type headache 29.7 23.0–36.4 [9, 23]
Migraine 16.0 10.0–22.0 [21, 22]
Mixed¶ 38.2 36.4–40.0 [20, 23]
Interstitial cystitis 15.4 12.0–22.4 [9, 24–27]
Chronic fatigue syndrome 55.2 15.6–80 [9, 28, 29]
Vulvar vestibular syndrome 23.4 15.6–31.2 [30, 31]
Gulf War syndrome 17.6 2.0–33.8 [32–34]
∗Prevalence of FMS in other CSS conditions with a single study has been discussed in the text.
¶Mixture of tension-type headache and migraine.
although they are present to a lesser extent in other members
of CSS as a manifestation of CS [6].
It was not until 1990s when the presence of FMS in many
chronic diseases with structural pathology was generally
recognized among the researchers. Now, it is known
that FMS is signiﬁcantly associated with RA [10, 38–41],
systemic lupus (SLE) [42–48], ankylosing spondylitis (AS)
[49, 50], osteoarthritis (OA) [51], diabetes mellitus [52, 53],
endometriosis [54], hypothyroidism [55], and inﬂammatory
bowel disease [56, 57]( Table 2).
CS alone (without FM) has been reported in juvenile
chronic arthritis [59], OA [60–65], endometriosis [66],
carpal tunnel syndrome [67–69], chronic pancreatitis [70,
71], and Parkinson’s disease [72–74]. It is likely that CS
is the harbinger of future development of FMS, as may
be demonstrated in future studies. It is as if “ﬁbro, ﬁbro
everywhere and not a place for the (rational) eyes to hide.”
An interesting question is, and data have not emerged yet
to answer it, are other members of the CSS family, such as
IBS and myogenic TMD also associated with these chronic
diseases with structural pathology?
FMS has been reported also in Sjogren’s syndrome,
hepatitis C, HIV, and other infections, for example, Lyme
disease. True to the title of this essay, however, only those
diseases that usually cause pain have been described in this
paper.
5. CriticalEvaluationof the Studies:
Imperfect butthe Associations AreReal
A number of studies, both in the category of FMS in CSS
and FMS in DWSP, are less than satisfactory because of small
numbers, unspeciﬁed or nonstandard criteria used (both for
FMS and the associated diseases), an absence of, or the use of
inappropriate controls as well as inappropriate statistics, for
example, a failure to adjust for multiple comparisons. Lack
of blindness, a critical procedure to avoid bias, was universal,
as is the case with most published studies in any disease.
However, reported prevalence rates of FMS in general
were much higher than that in the general population. Since
the results of all the studies converge in the same direction,
that is, increased prevalence of FMS compared with study or
population controls, it seems proper to conclude that true
associations of FMS with the diseases discussed exist.
6.Pathophysiological Mechanisms of Disease
Associationswith FMS: Central Sensitization
Is Central
6.1. CS and CSS Conditions. Central and common to CSS
diseases are CS. The pathophysiology of CS has been
discussed elsewhere [6, 8, 75] and is beyond the scope of this
essay.Tobesure,themechanismsinvolvedinCSaremultiple
and complex [75]. Some of these mechanisms involve tem-
poral summation (windup), long-term potentiation (LTP),
heterosynapticpotentiation,adysfunctionaldescendingpain
inhibition, and an activation of the descending facilitatory
pathway [75]. It is also evident that input in one set of
nociceptive ﬁbers ampliﬁes subsequent response to other
nonstimulated noceptive or nonnociceptive ﬁbers (het-
erosynaptic potentiation). Such phenomena explain diﬀuse
distribution of pain as well as allodynia.
After many years of research in animal models, human
volunteers, and chronic pain conditions, several facts have
emerged. While a noxious stimulus at some point in the
past might have initiated increased neuronal sensitivity, no
further nociceptive stimulus is necessary to perpetuate and
sustain a state of hyperalgesia or allodynia. That sustained
pain is no longer nociceptive in nature, provoking some
physicians to take recourse to such derogatory lexicons as
neurotics, malingerers, somatizers, and “medically unex-
plained symptoms” (read “your symptoms are all in your
head”). In other cases, following the adequate initial noci-
ceptive input, only a very low level of nociceptive stimulus
was needed to maintain the CS [75].
With regards to tender points, it is often stated that they
are subjective (thus there is an issue of secondary gain here),
butCSmaybeelicitedbystimulithatdonotrequirepatient’s
subjective response and are thus purely objective. Such an
objective “test” is nociceptive spinal ﬂexion reﬂex that has
been demonstrated in several CSS conditions [6]. Using
ascending and random paradigms, it has been demonstrated4 Pain Research and Treatment
Table 2: Prevalence of ﬁbromyalgia syndrome (FMS) in chronic painful diseases with structural (organic) pathology (DWSP)
Chronic DWSP % prevalence of FMS (mean) % prevalence of FMS (range) Reference no.
Rheumatoid arthritis 15.4 12.2–19.8 [10, 38–41]
SLE 16.2 5.0–25.3 [42–48, 58]
Ankylosing spondylitis∗ 30.4 10.8–50.0 [49, 50]
Osteoarthritis 11.0 — [51]
Diabetes mellitus∗ 17.5 17.0–18.0 [52, 53]
Endometriosis 5.9 — [54]
Hypothyroidism 34.0 — [55]
Crohn’s disease 26.0 3.0–49.0 [56, 57]
Ulcerative colitis 11.4 3.7–49.0 [56, 57]
SLE: systemic lupus erythematosus.
∗Female patients only.
that response bias does not play a major role in pain report
during CS testing in human pain laboratory [76]. Other
objective ﬁndings are brain abnormalities by neuroimaging
techniques and measurements of several neurotransmitters,
for example, substance P, serotonin and its metabolites, and
n e r v eg r o w t hf a c t o r[ 7].
There is evidence that CS is causal and not just an
eﬀect of chronicity among CSS members [6]. Asymptomatic
individuals displaying CS in conjunction with genetic factors
develop a CSS condition when followed up for a few years
(see [6] for speciﬁc studies). Further, several centrally acting
medications eﬃcacious in FMS decrease CS [6].
The relative role of peripheral and central factors and
ascending and descending pathways in ﬁbromyalgia and
other CSS diseases are not known at this time. In FMS,
drugs acting on both ascending pathway (pregabalin) and
descending pathway (e.g., duloxetine and milnacipran) are
equally eﬀective in general. In an editorial that evaluates
several controlled studies, Martin Ingar states that descend-
ing pain control plays an important role in FMS [77]. It
has been asserted that peripheral nociception is essential
for CS in FMS [78]. In support of this view, the author
cites a number of studies showing muscle abnormalities in
FMS. Unfortunately, these studies did not include controls
matched for aerobic ﬁtness employing VO2max, nor were
they blinded. Bennett and his colleagues showed that 80%
of the FMS patients were not physically ﬁt as assessed
by maximal oxygen uptake (VO2max) [79]. The authors
emphasized the need for using sedentary controls in FMS
muscle studies.
Using appropriately matched sedentary controls using
VO2max, Simms et al. showed that energy metabolism in
trapezius and tibialis anterior muscles of FMS patients,
including intracellular pH, was normal when compared with
controls [80]. In our initial uncontrolled muscle biopsy
study, mitochondrial and other changes were found [81].
However, in our subsequent activity-controlled (indirectly
sedentary controlled) and blinded study, no abnormalities in
the trapezius muscle were noted in FMS as compared with
thecontrols[82](thisistheonlyblindedmusclebiopsystudy
in the literature to my knowledge).
However, contribution of peripheral input (versus
pathology) in FMS has been demonstrated [83]. Staud et al.
showed that lidocaine injection in the trapezius muscle
increased pressure pain threshold locally in both FMS
patients and controls, but placebo injection did not. In
addition, heat hyperalgesia of FMS patients in remote
site (forearm) was also decreased, suggesting the role of
peripheral input in heat hyperalgesia at a remote site (CS)
[83]. However, clinical pain rating was not aﬀected and
the nature of such nociceptive locus in the muscle (e.g.,
inﬂammation and ischemia) is not clear, nor is it known if
hyperalgesia from other forms of stimuli is maintained by
peripheral nociception.
In a recent placebo-controlled study [84], Aﬀaitati et al.
have shown that injection of a TrP with local anesthetic deep
in the muscle tissue (the placebo group received injections
near the trigger points, presumably in superﬁcial tissue)
produced a decrease in number as well as pain intensity in
TrP with an increase in pain pressure threshold both in TrP
and nonpainful sites.
In the same study [84], the investigators applied
hydroelectrophoresis to a FMS group having a painful joint
or an area of rotator cuﬀ partial tear using diclofenac and
betamethasone in agarose gel in a tube as well as electrodes
that were connected to a computerized current stimulator.
The placebo group received a gel without active ingredients.
T h ea c t i v et r e a t m e n tg r o u pr e d u c e dt h e i rF M Sp a i na s
well as number of TP, and the pressure pain threshold in
nonpainful areas also increased. The placebo group did not
demonstrate such improvement. This study also suggests
that peripheral input contributes to CS. Interestingly,
generalized hyperalgesia signiﬁcantly improved in women
with endometriosis following hysterectomy [66].
From the above discussion, it is clear that peripheral
input is necessary in at least some patients. Visceral aﬀerent
input [75] may be operative in IBS [85], interstitial cystitis,
and chronic pelvic pain. These patients also demonstrate
somatic sensitization. Since no deﬁnite nociceptive pathol-
ogy has been convincingly demonstrated in the peripheral
tissue, is it possible that CS itself contributes to peripheral
input in a vicious cycle? It is relatively easy to conceptualize
the role of initial peripheral inﬂammation in cases of
signiﬁcant trauma incidents, for example, motor vehicle
accident (MVA) and falls. In a “hit and run” phenomenon,
the initial inﬂammation triggers CS and is maintained withPain Research and Treatment 5
little or no further peripheral input as is well accepted from
experimental models [75].
From other experimental examples, it seems that periph-
eral input may not be necessary at all [75]. Such appar-
ently “innate” CS may be due to genetics, early adverse
childhood experience, prenatal stress, chemical exposure (as
in multiple chemical sensitivity), dopamine deﬁciency (as
in restless legs syndrome and Parkinson’s disease), other
neurotransmitter or endocrine abnormalities, past trauma
as mentioned above (MVA, falls), severe and continuous
sleep deprivation, and psychological trauma or stress. Other
factors, for example, infection, autonomic nervous system
dysfunction, inﬂammatory cytokines, and CNS microglia
and astrocytes may contribute to CS of CSS conditions. The
issue of relative role of peripheral and central factors in CS
must be regarded unresolved at this time. Our best guess is
thatbotharenecessaryandtherelativecontributionwillvary
from individual to individual, partly determined by genetic
predisposition.
It is interesting to speculate that there are subgroups of
CS.Somemayresultfromobviousperipheralsource(suchas
trauma,localinﬂammation,neuritis,orarthritis),andothers
areindependentofsuchperipheralinputbecauseofgenetics,
sleep deprivation, or psychological distress. Moreover, some
may predominantly result from reduced descending inhibi-
tion,othersfromdescendingfacilitation,andyetothersfrom
cortical or limbic activation. Future research may determine
that certain drugs work predominantly in one pathway but
not the others. It is entirely possible that all of the neural
pathways are involved in a given individual, likely in an
interacting way.
6.2. FMS in Chronic Painful Diseases with Structural Pathol-
ogy. An obvious source of nociception is present in RA,
OA, AS, SLE (associated with arthritis), endometriosis, and
inﬂammatory bowel disease. Pain often causes poor sleep
that in turn may contribute to CS. Neuritis may contribute
to CS and subsequent FMS in diabetes mellitus. The mecha-
nism of CS in hypothyroidism [55] is not obvious. However,
this is a single study and needs further conﬁrmation. RA
patients with concomitant FMS have worse disease activity
with joint swelling and tenderness [40, 41] and greater psy-
chosocial distress [41]. There were no signiﬁcant diﬀerences
in SLE activity between SLE patients with or without FMS.
FMSfeatures,forexample,fatigueandpoorsleep,weremore
commonintheSLEplusFMSgroup.Whetherinﬂammation,
cytokines, genetics, or endocrine factors are contributory
is unknown. Concomitant presence of FMS in the above
diseases has universally shown greater disability in all studies
that addressed the function and overall symptom severity.
Patients with OA plus FMS had greater sleep diﬃcul-
ties (70%) that correlated with fatigue [51]. Those with
sleep problems had more severe OA, and depression was
also common. It has been suggested that repeated acute
inﬂammation in chronic pancreatitis leads to sensitization
of peripheral pancreatic nerves that subsequently lead to
central neuroplasticity [86]. In Parkinson’s disease, CS has
been explained on the basis of somatosensory function of the
basalganglia.TheroleofD2receptorsinpainprocessingand
a deﬁciency of dopaminergic inhibition have been suggested
[72].
6.3. Brain Changes in Chronic Pain. Until recently, central
sensitization was attributed to an abnormal function of
the nociceptive/antinociceptive neurons at diﬀerent levels of
neuroaxis leaving the brain structure intact. The advent of
magnetic resonance imaging has demonstrated that not only
there is a functional reorganization of the cerebral cortex in
chronic pain, for example, FMS, IBS, and chronic back pain,
but also there is actual anatomic decrease in the gray matter
of various regions of the brain. This imaging technique
is called MR morphometry. Although areas involved vary
depending on the type of chronic pain, a general picture has
emerged to involve the cingulated cortex, the orbitofrontal
cortex, the insula, and the dorsal pons, representing a
c o m m o n“ b r a i ns i g n a t u r e ”[ 87]. The anterior cingulate
cortex (ACC) plays a particularly important role in pain
modulation and analgesia. ACC interacts with orbitofrontal
cortex, PAG, and the amygdala. Together, it plays a crucial
roleinendogenouspaincontrol.Ananatomicshrinkagethus
may contribute to enhanced sensitivity in chronic pain.
In FMS, a reduction in gray matter has been demon-
strated in left parahippocampal gyrus, cingulated gyrus,
insula, and medial frontal cortex. A decrease in gray matter
involves simple reduction of cell size or atrophy of the
neurons or the glia and does not necessarily imply neuronal
destruction.Thus,withpropertreatmentofchronicpain,the
gray matter may regain its original size [87]. An important
question is whether continued and prolonged chronic pain
will lead to irreversible degeneration. A crucial issue is
whether the morphometric changes with atrophy of the gray
matterarethecauseorconsequenceofchronicpain. Itseems
that the changes result from ongoing CS. If so, centrally
acting medications that diminish CS may retard or even
reverse the gray matter change.
7.Signiﬁcanceof DiseaseAssociations
with FMS: Implication for Science and
Patient Care
The concept of mutual association of the CSS has helped
to better diagnose these conditions without extensive and
unnecessary investigations. Recognition of an objective
pathophysiological basis has contributed to a better under-
standing and treatment as well as physician acceptance
of these common problems that cause much distress to
our patients. Thus, it has helped us to understand why
nonsteroidal anti-inﬂammatory drugs that act peripherally
are not eﬃcacious in FMS and why centrally acting medi-
c a t i o n sa sw e l la sn o n p h a r m a c o l o g i ca p p r o a c h ,f o re x a m p l e ,
cognitive behavioral therapy (that act centrally), should be
the appropriate management approach. Since total disease
burden with functional impairment is greater in those with
many associated conditions, a practicing physician should
treat all these conditions for optimal results.
Since pathophysiologically the CSS disorders are similar,
discovery of a certain mechanism and eﬀective medication6 Pain Research and Treatment
in one disease may be applied to others. In developing
new therapy, the eﬀect of a new medication on CS may be
investigated before undertaking expensive clinical trials.
The most important implication of concomitant FMS
in chronic diseases with structural pathology is its recog-
nition for optimal management. For example, when FMS
symptoms (e.g., increased pain and fatigue) with multiple
tender points are present in RA or SLE, they should not be
automatically attributed to increased activity of these dis-
eases and one should not prescribe higher doses of a biologic
agent or corticosteroids without proper TP examination
and laboratory evaluation. Appropriate attention should be
directed to the management of FMS with centrally acting
medications, cognitive behavioral therapy, and management
of sleep problems. A patient with severe pain in OA
will require both peripherally acting analgesics as well as
those that act centrally, such as cyclobenzaprine, pregabalin,
duloxetine, and milnacipran.
8. Summary: A Few Words to Store and Ponder
CSS diseases are based on a neurochemical pathology, and
they are not psychological or psychiatric illnesses. Associated
psychosocial issues, as may be present in any chronic disease,
including RA or SLE or cancer should be addressed. CSS
conditions are mutually associated, and a particular patient
may have several of them. Multiple symptoms in these
patients have a demonstrable pathophysiological basis and
donotrepresentsomatization.ItismostimportantthatFMS
is suspected in all chronic diseases with structural pathology,
for example, RA, SLE, OA, and AS, so that proper diagnosis
and management can be undertaken.
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